TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its ...
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a ...
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA ...
TransCode Therapeutics ( (RNAZ) ) has provided an update.
Board of Directors has approved a 1-for-33 reverse stock split. The reverse stock split was approved by TransCode’s ...
Transcode Therapeutics shares are trading lower by 11% to 34 cents Monday afternoon. The company announced its Board's ...
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical-stage oncology company, announced today that its Board of Directors has approved a 1-for-33 reverse stock split. The decision ...
(MENAFN- GlobeNewsWire - Nasdaq) BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology CompanyTM committed to more effectively treating cancer ...
(RTTNews) - TransCode Therapeutics, Inc. (RNAZ), a clinical-stage oncology company focused on RNA therapeutics, announced on Wednesday that it has entered into a securities purchase agreement to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback